沙库巴曲/缬沙坦对慢性心力衰竭患者心律失常影响的研究进展

doi:10.3969/j.issn.1004-583X.2023.05.014

摘要/Abstract

摘要：

慢性心力衰竭是绝大多数心血管疾病的终末期阶段,心力衰竭患者常并发各种类型的心律失常。沙库巴曲/缬沙坦(sacubitril/valsartan,S/V)是首个血管紧张素受体-脑啡肽酶抑制剂,已被推荐为射血分数下降性心力衰竭患者的一线治疗, 但S/V对心律失常的影响存在争议。有研究认为S/V可以减少心律失常的发生,但也有研究认为S/V并不能减少心律失常的发生,甚至有案例报道认为S/V有致心律失常作用。本文通过综述S/V对慢性心力衰竭患者心律失常影响的研究进展,旨在为临床提供依据。

中图分类号:

R541.6

尚蒙, 王礼琳. 沙库巴曲/缬沙坦对慢性心力衰竭患者心律失常影响的研究进展[J]. 临床荟萃, 2023, 38(5): 459-464.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.05.014

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I5/459

参考文献 53

[1]	Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A report from the American Heart Association[J]. Circulation, 2023, 147(8):e93-e621.
[2]	Van Nuys KE, Xie Z, Tysinger B, et al. Innovation in heart failure treatment: Life expectancy, disability, and health disparities[J]. JACC Heart Fail, 2018, 6(5):401-409. doi: 10.1016/j.jchf.2017.12.006 URL
[3]	Wang H, Chai K, Du M, et al. Prevalence and incidence of heart failure among urban patients in China: A national population-based analysis[J]. Circ Heart Fail, 2021, 14(10):e008406.
[4]	Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)[J]. J Clin Pharmacol, 2010, 50(4): 401-414. doi: 10.1177/0091270009343932 URL
[5]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[6]	Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation, 2017, 136(6):e137-e161.
[7]	中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志, 2018, 46(10):760-789.
[8]	Writing Committee Members; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure[J]. J Card Fail, 2022, 28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010 pmid: 35378257
[9]	Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients[J]. Eur Heart J, 2015, 36(30):1990-1997. doi: 10.1093/eurheartj/ehv186 pmid: 26022006
[10]	Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2019, 108(10):1074-1082. doi: 10.1007/s00392-019-01440-y pmid: 30788621
[11]	张常莹, 刘晓宇, 李晓燕, 等. 沙库巴曲缬沙坦对植入了心脏除颤器的心力衰竭患者室性心律失常发生的影响[J]. 中国心脏起搏与心电生理杂志, 2021, 35(4):305-309.
[12]	Russo V, Ammendola E, Gasperetti A, et al. Add-on therapy with sacubitril/valsartan and clinical outcomes in CRT-D nonresponder patients[J]. J Cardiovasc Pharmacol, 2022, 79(4):472-478. doi: 10.1097/FJC.0000000000001202 URL
[13]	孙劼, 冯力, 董剑廷, 等. 沙库巴曲缬沙坦治疗HFrEF并室性心律失常的疗效研究[J]. 深圳中西医结合杂志, 2021, 31(12):147-149.
[14]	裴强, 王强, 羊镇宇, 等. 沙库巴曲缬沙坦对慢性心力衰竭患者的抗室性心律失常作用[J]. 实用心电学杂志, 2021, 30(5):342-345.
[15]	Curtain JP, Jackson AM, Shen L, et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF[J]. Eur J Heart Fail, 2022, 24(3):551-561. doi: 10.1002/ejhf.v24.3 URL
[16]	Medeiros P, Coelho C, Costa-Oliveira C, et al. The effect of sacubitril-valsartan on ventricular arrhythmia burden in patients with heart failure with reduced ejection fraction[J]. Cureus, 2023, 15(2):e34508-e34514.
[17]	El-Battrawy I, Pilsinger C, Liebe V, et al. Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients[J]. J Clin Med, 2019, 8(10):1582. doi: 10.3390/jcm8101582 URL
[18]	Dong Y, Zhai Z, Wang J, et al. Angiotensin receptor-neprilysin inhibitor delays progression from paroxysmal to persistent atrial fibrillation[J]. Sci Rep, 2023, 13(1):3140. doi: 10.1038/s41598-023-30349-w pmid: 36823222
[19]	Chen Q, Chen Y, Qin F, et al. Effect of sacubitril-valsartan on restoration and maintenance of sinus rhythm in patients with persistent atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:870203.
[20]	Wang Q, Zhuo C, Xia Q, et al. Sacubitril/valsartan can reduce atrial fibrillation recurrence after catheter ablation in patients with persistent atrial fibrillation[J]. Cardiovasc Drugs Ther, 2023, 37(3):549-560. doi: 10.1007/s10557-022-07315-1
[21]	Yang L, Zhang M, Hao Z, et al. Sacubitril/valsartan attenuates atrial structural remode-lling in atrial fibrillation patients[J]. ESC Heart Fail, 2022, 9(4):2428-2434. doi: 10.1002/ehf2.13937 pmid: 35437929
[22]	Zhu T, Zhang W, Yang Q, et al. Effect of angiotensin receptor-neprilysin inhibitor on atrial electrical instability in atrial fibrillation[J]. Front Cardiovasc Med, 2022, 9:1048077.
[23]	Primessnig U, Deißler PM, Wakula P, et al. Effects of BNP and sacubitrilat/valsartan on atrial functional reserve and arrhythmogenesis in human myocardium[J]. Front Cardiovasc Med, 2022, 9:859014.
[24]	Suo Y, Yuan M, Li H, et al. Sacubitril/valsartan improves left atrial and left atrial appendage function in patients with atrial fibrillation and in pressure overload-induced mice[J]. Front Pharmacol, 2019, 10:1285. doi: 10.3389/fphar.2019.01285 pmid: 31736759
[25]	Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias[J]. Heart Rhythm, 2014, 11(7):1109-1116. doi: 10.1016/j.hrthm.2014.04.024 pmid: 24837348
[26]	Banasik G, Segiet O, Elwart M, et al. LV mechanical dispersion as a predictor of ventricular arrhythmia in patients with advanced systolic heart failure: A pilot study[J]. Herz, 2016, 41(7): 599-604. pmid: 26883898
[27]	Valentim Gonçalves A, Pereira-da-Silva T, Galrinho A, et al. Antiarrhythmic effect of sacubitril-valsartan: Cause or consequence of clinical improvement?[J]. J Clin Med, 2019, 8(6): 869. doi: 10.3390/jcm8060869 URL
[28]	Sarrias A, Bayes-Genis A. Is sacubitrilat/valsartan(also) an antiarrhythmic drug?[J]. Circulation, 2018, 138(6):551-553. doi: 10.1161/CIRCULATIONAHA.118.034755 pmid: 30354612
[29]	Eiringhaus J, Wünsche CM, Tirilomis P, et al. Sacubitrilat reduces pro-arrhythmogenic sarcoplasmic reticulum Ca2+ leak in human ventricular cardiomyocytes of patients with end-stage heart failure[J]. ESC Heart Fail, 2020, 7(5):2992-3002.
[30]	Chang PC, Lin SF, Chu Y, et al. LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model[J]. Cardiovasc Ther, 2019, 2019:6032631.
[31]	Tsai YN, Cheng WH, Chang YT, et al. Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia[J]. J Cardiol, 2021, 78(4):275-284. doi: 10.1016/j.jjcc.2021.04.011 URL
[32]	Zhou Y, Rui S, Tang S, et al. Exploration of mechanisms of sacubitril/valsartan in the treatment of cardiac arrhythmias using a network pharmacology approach[J]. Front Cardiovasc Med, 2022, 9:829484.
[33]	Murray GL, Colombo J. Sudden cardiac death in the general population: Can we improve risk stratification and prevention?[J]. Int J Angiol, 2021, 30(4):271-276. doi: 10.1055/s-0041-1729629 URL
[34]	Kusaka H, Sueta D, Koibuchi N, et al. LCZ696, angiotensin Ⅱ receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone[J]. Am J Hypertens, 2015, 28(12):1409-1417. doi: 10.1093/ajh/hpv015 URL
[35]	Giallauria F, Vitale G, Pacileo M, et al. Sacubitril/valsartan improves autonomic function and cardiopulmonary parameters inpatients with heart failure with reduced ejection fraction[J]. J Clin Med, 2020, 9(6):189. doi: 10.3390/jcm9010189 URL
[36]	Bunsawat K, Ratchford SM, Alpenglow JK, et al. Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study[J]. Auton Neurosci, 2021, 235:102834.
[37]	Castrichini M, Manca P, Nuzzi V, et al. Sacubitril/valsartan induces global cardiac reverse remodeling in long-lasting heart failure with reduced ejection fraction: Standard and advanced echocardiographic evidences[J]. J Clin Med, 2020, 9(4):906. doi: 10.3390/jcm9040906 URL
[38]	Sun Y, Song S, Zhang Y, et al. Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure[J]. ESC Heart Fail, 2022, 9(1):667-675.
[39]	李倩, 李昕, 李路安, 等. 沙库巴曲缬沙坦通过逆转高血压大鼠心房结构重塑降低房颤易感性[J]. 中国药理学通报, 2021, 37(5):631-637.
[40]	Li LY, Lou Q, Liu GZ, et al. Sacubitril/valsartan attenuates atrial electrical and structural remodelling in a rabbit model of atrial fibrillation[J]. Eur J Pharmacol, 2020, 881:173120.
[41]	Li SN, Zhang JR, Zhou L, et al. Sacubitril/valsartan decreases atrial fibrillation susceptibility by inhibiting angiotensin Ⅱ-induced atrial fibrosis through p-Smad2/3, p-JNK, and p-p38 signaling pathways[J]. J Cardiovasc Transl Res, 2022, 15(1):131-142. doi: 10.1007/s12265-021-10137-5
[42]	Park JJ, Park JH, Hwang IC, et al. Left atrial strain as a predictor of new-onset atrial fibrillation in patients with heart failure[J]. JACC Cardiovasc Imaging, 2020, 13(10):2071-2081. doi: 10.1016/j.jcmg.2020.04.031 pmid: 32682715
[43]	De Vecchis R, Paccone A, Di Maio M. Favorable effects of sacubitril/valsartan on the peak atrial longitudinal strain in patients with chronic heart failure and a history of one or more episodes of atrial fibrillation: A retrospective cohort study[J]. J Clin Med Res, 2020, 12(2): 100-107. doi: 10.14740/jocmr4076 pmid: 32095179
[44]	Chiu MH, Howlett JG, Kuriachan VP, et al. A case of palpitations due to T-wave oversensing caused by sacubitril/valsartan[J]. Can J Cardiol, 2018, 34(8):1089.e1-1089.e3.
[45]	Vicent L, Juárez M, Martín I, et al. Ventricular arrhythmic storm after initiating sacubitril /valsartan[J]. Cardiology, 2018, 139(2):119-123. doi: 10.1159/000486410 URL
[46]	Vicent L, Méndez-Zurita F, Viñolas X, et al. Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation[J]. Heart Vessels, 2020, 35(1):136-142. doi: 10.1007/s00380-019-01454-6 pmid: 31230095
[47]	Vicent L, Martínez-Sellés M. Can sacubitril/valsartan have a proarrhythmic effect in some high-risk patients?[J]. Cardiology, 2019, 143(1):34-35. doi: 10.1159/000500193 pmid: 31330516
[48]	Weir RAP. Sacubitril/valsartan and mexiletine: A proarrhythmic combination?[J]. Cardiology, 2019, 142(1):4-6. doi: 10.1159/000497071 pmid: 30852576
[49]	Kohjitani A, Miyawaki T, Funahashi M, et al. Mexiletine inhibits nonadrenergic noncholinergic lower oesophageal sphincter relaxation in rabbits[J]. Eur J Pharmacol, 2003, 465(1-2):145-151. pmid: 12650844
[50]	Iborra-Egea O, Gálvez-Montón C, Roura S, et al. Mechanisms of action of sacubitril/valsartan on cardiac remodeling: A systems biology approach[J]. NPJ Syst Biol Appl, 2017, 3:12. doi: 10.1038/s41540-017-0013-4 pmid: 28649439
[51]	Vecchio N. Potential drug interactions in critically Ill patients: Sacubitril/valsartan and mexiletine[J]. Cardiology, 2019, 142(2):81-82. doi: 10.1159/000499193 pmid: 31079109
[52]	Langenickel TH, Jordaan P, Petruck J, et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization[J]. Eur J Clin Pharmacol, 2016, 72(8):917-924. doi: 10.1007/s00228-016-2062-9 pmid: 27083930
[53]	Okutucu S, Oto A. Electrical storm after initiating sacubitril/valsartan: Arrhythmic paradox[J]. Cardiology, 2019, 142(1):24-25. doi: 10.1159/000496737 pmid: 30865945

沙库巴曲/缬沙坦对慢性心力衰竭患者心律失常影响的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 53

相关文章 15

编辑推荐

Metrics

本文评价

[1]	马丽娜, 焦焕利, 曹振华. 慢性非缺血性心功能衰竭合并血栓栓塞及药物治疗研究进展[J]. 临床荟萃, 2024, 39(1): 75-79.
[2]	段芳, 崔炜. 血管扩张剂在急性心力衰竭救治中的应用原则[J]. 临床荟萃, 2023, 38(9): 773-778.
[3]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[4]	于晓东, 任晓艺, 刘美霞. 左西孟旦应用于机体重要器官疾病的研究进展[J]. 临床荟萃, 2023, 38(6): 573-576.
[5]	王震, 杨晓月, 李少杰, 王贤, 陈淑霞, 谷剑. 射血分数保留的心力衰竭合并心房颤动患者临床特征及再入院危险因素[J]. 临床荟萃, 2023, 38(4): 308-314.
[6]	王凤华, 魏茂提. 干式桑拿疗法治疗慢性心力衰竭的研究进展[J]. 临床荟萃, 2023, 38(4): 369-372.
[7]	张芳, 张伊超, 贾辛未, 李建龙, 陈春红. 心房颤动高CHA2DS2-VASc评分≥75岁住院患者随访1年结果分析[J]. 临床荟萃, 2023, 38(2): 117-120.
[8]	李娜娜, 江珊. 血清同型半胱氨酸、胱抑素C、超敏C-反应蛋白水平对急性ST段抬高型心肌梗死患者PCI术后并发心力衰竭的预测价值[J]. 临床荟萃, 2023, 38(2): 121-125.
[9]	邓媛媛, 岑梅, 金铭, 赵丽静, 张旖旎, 张智香. 慢性心力衰竭合并低蛋白血症患者营养管理的研究进展[J]. 临床荟萃, 2022, 37(9): 838-841.
[10]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[11]	章敬水, 徐亚男, 王钧, 杨毅, 姜海兵, 唐龙, 王贤平, 邵名亮. 新发的不同类型心力衰竭合并心房颤动的临床特点和远期预后分析[J]. 临床荟萃, 2022, 37(6): 504-509.
[12]	张宏涛, 杨雨, 王志奎. 腹膜透析患者心力衰竭治疗药物研究进展[J]. 临床荟萃, 2022, 37(6): 556-559.
[13]	李姮, 李永辉, 孙小强, 王琳, 何峰. 窦性心律慢性心力衰竭患者抗凝治疗安全性及有效性系统评价[J]. 临床荟萃, 2022, 37(5): 406-411.
[14]	王润青, 王谦, 廖健雄. SGLT2抑制剂对2型糖尿病患者心血管结局影响的网状meta分析[J]. 临床荟萃, 2022, 37(12): 1061-1073.
[15]	周子涵, 崔炜. 心血管系统常用药物对新型冠状病毒肺炎感染风险及不良预后的影响[J]. 临床荟萃, 2022, 37(10): 869-888.